Femasys (FEMY) announces a partnership with CNY Fertility, a national provider of fertility services across the U.S. CNY Fertility will provide the Company’s FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of 11 locations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys’s Strategic Expansion and Promising Clinical Results Justify Buy Rating
- Femasys secures partnerships for commercialization of FemBloc in Spain
- Femasys Achieves CE Mark for FemBloc, Paving the Way for European Market Entry and Justifying Buy Rating
- Femasys announces FemBloc delivery system approval in Europe
- Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation